Zobrazeno 1 - 10
of 325
pro vyhledávání: '"WeiJun Fu"'
Autor:
ZiYan An, QiWei Zhou, JinPeng Shao, ShuWei Xiao, Kun Zhao, WenJie Wei, YangYang Wu, Yong Song, Qing Yuan, WeiJun Fu, Xu Zhang
Publikováno v:
BMC Primary Care, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background The impact of lower urinary tract symptoms (LUTS) on the quality of life of patients with benign prostatic hyperplasia (BPH) has been rarely reported. Additionally, the challenges faced by these patients in seeking medical care ha
Externí odkaz:
https://doaj.org/article/2993053223a147bb9c3124670fe87eef
Autor:
Hua Jiang, Lu Li, Meiyu Guo, Meizhang Li, Hao Wu, Xiaomei Chen, Mingzhao Gao, Qianqian Xu, Jia Mi, Canchan Cui, Weijun Fu
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM patients with RI remains unclear, our objective was to evaluate the efficacy of daratumu
Externí odkaz:
https://doaj.org/article/302e5dbd9ad74865a01f97feb11fa76a
Autor:
Huixing Zhou, Yuan Jian, Juan Du, Junru Liu, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Wenming Chen, Weijun Fu, Juan Li, Wen Gao
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9085-9096 (2023)
Abstract Background The present study intended to establish a predictive nomogram for early relapse (ER) ( UNL, and response less than very good partial response (VGPR) after ASCT. The calibration curve showed good fitness between the nomogram predic
Externí odkaz:
https://doaj.org/article/7df83de9156e4d11a582d740c033c378
Publikováno v:
Molecules, Vol 29, Iss 5, p 973 (2024)
A metal-free electrochemical oxidative difluoroethylation of 2-arylbenzimidazoles was accomplished, which provided an efficient strategy for the synthesis of MeCF2-containing benzo[4,5]imidazo[2,1-a]-isoquinolin-6(5H)-ones. In addition, the method al
Externí odkaz:
https://doaj.org/article/5d015e88a0514d46b164ec53dfff0863
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDespite significant therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Pomalidomide is the third Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multiple myeloma.
Externí odkaz:
https://doaj.org/article/d77d2c900c2c4d9289563405ff751352
Autor:
Juan Du, Weijun Fu, Hua Jiang, Baoxia Dong, LI Gao, LI Liu, Jian Ge, Aili He, Lu LI, Jing Lu, Xiequn Chen, Jia Liu, Qi Zhang, Jiaping He, Lihong Weng, Hua Zhang, Lianjun Shen, Wei Cao, Wenling LI
Publikováno v:
HemaSphere, Vol 7, p e84060bf (2023)
Externí odkaz:
https://doaj.org/article/72b8e784356840ad85e3d5609b24b250
Autor:
Jian‑qing MI, Wan‑hong Zhao, Li‑juan Chen, Weijun Fu, Bai‑yan Wang, Jie Xu, Jie Liu, Shi‑wei Jin, Han Zhu, Juan Du, Hua Jiang, Huabin Sun, Yehui Jia, Xiao‑hu Fan, Jian‑yong LI, Jian Hou, Zhu Chen, Wang‑gang Zhang, Ai‑li He, Sai‑juan Chen
Publikováno v:
HemaSphere, Vol 7, p e9841889 (2023)
Externí odkaz:
https://doaj.org/article/dc0f15ce4b87456ea5d56b80177fbfc5
Autor:
Lihua Qiu, Tingyu Wang, Xiuhua Sun, Hang Su, Junning Cao, Zhi-Ming LI, Yuqin Song, LI Zhang, Dengju LI, Huijing Wu, Wei Zhang, Junmin LI, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng LI, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei LI, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun LI, Shuhua Yi, Lugui Qiu
Publikováno v:
HemaSphere, Vol 7, p e37624bc (2023)
Externí odkaz:
https://doaj.org/article/00ba39c9e3dd4c03ada9c800daf17187
Autor:
Xiuhua Sun, Tingyu Wang, Lihua Qiu, Hang Su, Junning Cao, Zhi-Ming LI, Yuqin Song, LI Zhang, Dengju LI, Huijing Wu, Wei Zhang, Junmin LI, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng LI, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei LI, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun LI, Shuhua Yi, Lugui Qiu
Publikováno v:
HemaSphere, Vol 7, p e46591f9 (2023)
Externí odkaz:
https://doaj.org/article/15381915b0f04f48bee2299143d8860b
Autor:
Lugui Qiu, Zhongjun Xia, Chengcheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Fei Li, Zhuogang Liu, Xiequn Chen, Jing Liu, Aihua Wang, Yang Yu, Wenxi Xiang, Kevin Lynch, Zhinuan Yu, Weijun Fu
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated significant clinical benefit in patients with relapsed/refractory multiple myeloma (RRMM) who had disease refractory to a proteasome inhibitor (PI), an immunom
Externí odkaz:
https://doaj.org/article/7974db28b8e340529d70e4314a701e71